Literature DB >> 19387880

Urogenital atrophy.

J Calleja-Agius1, M P Brincat.   

Abstract

The major cause of urogenital atrophy in menopausal women is estrogen loss. The symptoms are usually progressive in nature and deteriorate with time from the menopausal transition. The most prevalent urogenital symptoms are vaginal dryness, vaginal irritation and itching. The classical changes in an atrophic vulva include loss of labial and vulvar fullness, with narrowing of the introitus and inflamed mucosal surfaces. Dyspareunia and vaginal bleeding from fragile atrophic skin are common problems. Other urogenital complaints include frequency, nocturia, urgency, incontinence and urinary tract infections. Atrophic changes of the vulva, vagina and lower urinary tract can have a large impact on the quality of life of the menopausal woman. However, hormonal and non-hormonal treatments can provide patients with the solution to regain previous level of function. Therefore, clinicians should sensitively question and examine menopausal women, in order to correctly identify the pattern of changes in urogenital atrophy and manage them appropriately.

Entities:  

Mesh:

Year:  2009        PMID: 19387880     DOI: 10.1080/13697130902814751

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  15 in total

1.  The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study.

Authors:  P Diamond; S Hassonah; M Alarab; D Lovatsis; H P Drutz
Journal:  Int Urogynecol J       Date:  2012-04-25       Impact factor: 2.894

2.  Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.

Authors:  Rebekah A Burich; Neelima Rakesh Mehta; Gregory T Wurz; Jamie Lee McCall; Brittany E Greenberg; Katie E Bell; Stephen M Griffey; Michael W DeGregorio
Journal:  Menopause       Date:  2012-01       Impact factor: 2.953

Review 3.  A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Authors:  Mariana S Sousa; Michelle Peate; Sherin Jarvis; Martha Hickey; Michael Friedlander
Journal:  Ther Adv Med Oncol       Date:  2017-01-31       Impact factor: 8.168

Review 4.  Prosthetic surgery versus native tissue repair of cystocele: literature review.

Authors:  Salvatore Giovanni Vitale; Antonio Simone Laganà; Ferdinando Antonio Gulino; Alessandro Tropea; Susanna Tarda
Journal:  Updates Surg       Date:  2016-01-22

Review 5.  Histology of the vaginal wall in women with pelvic organ prolapse: a literature review.

Authors:  Laurent De Landsheere; Carine Munaut; Betty Nusgens; Catherine Maillard; Chrystèle Rubod; Michelle Nisolle; Michel Cosson; Jean-Michel Foidart
Journal:  Int Urogynecol J       Date:  2013-05-07       Impact factor: 2.894

Review 6.  Dermatosis associated with menopause.

Authors:  Pragya A Nair
Journal:  J Midlife Health       Date:  2014-10

Review 7.  Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Clin Interv Aging       Date:  2014-11-13       Impact factor: 4.458

Review 8.  Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy.

Authors:  Jae Jun Shin; Seul Ki Kim; Jung Ryeol Lee; Chang Suk Suh
Journal:  J Menopausal Med       Date:  2017-08-31

9.  Development of Hormonal Intravaginal Rings: Technology and Challenges.

Authors:  Fojan Rafiei; Hadi Tabesh; Shayan Farzad; Farah Farzaneh; Maryam Rezaei; Fateme Hosseinzade; Khosrow Mottaghy
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

Review 10.  Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

Authors:  Lin H Soe; Gregory T Wurz; Chiao-Jung Kao; Michael W Degregorio
Journal:  Int J Womens Health       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.